- Home
- WNW vs PASG Comparison
WNW vs PASG Comparison
Compare WNW & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WNW | PASG |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | China | United States |
| Employees | N/A | 27 |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 28.3M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WNW | PASG |
|---|---|---|
| Price | $1.75 | $8.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | 10.0K | ★ 28.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.28 |
| 52 Week High | $2.95 | $20.00 |
Technical Indicators
Market Signals| Indicator | WNW | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 62.33 | 40.48 |
| Support Level | $1.63 | $7.87 |
| Resistance Level | $1.89 | $8.85 |
| Average True Range (ATR) | 0.10 | 0.71 |
| MACD | 0.03 | 0.09 |
| Stochastic Oscillator | 74.51 | 24.88 |
Price Performance
Historical ComparisonAbout WNW Meiwu Technology Company Limited
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.